Analysis of fluid-phase mediators

European Respiratory Journal, Supplement

Volumn 20, Issue 37, 2002, Pages

  Kelly, M M ^a   Keatings, V ^a   Leigh, R ^a   Peterson, C ^a   Shute, J ^a   Venge, P ^a   Djukanovic R ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA 2 MACROGLOBULIN; CATHEPSIN B; CATHEPSIN G; CHEMOKINE; CYTOKINE; EOSINOPHIL CATIONIC PROTEIN; EOTAXIN; FIBRINOGEN; GAMMA INTERFERON; GELATINASE B; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTAMINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; NITRIC OXIDE; RANTES; TRANSFORMING GROWTH FACTOR BETA1; TRYPTASE; TUMOR NECROSIS FACTOR ALPHA; AUTACOID;

CONFERENCE PAPER; CYTOKINE PRODUCTION; ENZYME ASSAY; EOSINOPHIL; EXUDATE; HUMAN; LIQUID; MAST CELL; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN DETERMINATION; SPUTUM ANALYSIS; ASTHMA; BIOASSAY; CHEMISTRY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE STUDY; CYTOLOGY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; MALE; METHODOLOGY; RADIOIMMUNOASSAY; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; SPUTUM;

ASTHMA; BIOLOGICAL ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INFLAMMATION MEDIATORS; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RADIOIMMUNOASSAY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPUTUM;

EID: 0036715472     PISSN: 09041850     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (118)

1. Use of induced sputum cell counts to investigate airway inflammation in asthma
2. Indices of airway inflammation in induced sputum: Reproducibility and validity of cell and fluid-phase measurements
3. Repeatability of cellular and soluble markers of inflammation in induced sputum from patients with asthma
4. Induced sputum to assess airway inflammation: A study of reproducibility
5. The evaluation of a cell dispersion method of sputum examination
6. Analysis of induced sputum to examine the effects of prednisone on airway inflammation in asthmatic subjects
7. Between-observer repeatability of sputum differential cell counts. Influence of cell viability and squamous cell contamination
8. Cytokine concentrations in sputum from patients with cystic fibrosis and their relation to eosinophil activity
9. The effect of processing on inflammatory markers in induced sputum
10. Comparison of samples collected by sputum induction and bronchoscopy from asthmatic and healthy subjects
11. Cell infiltration, ICAM-1 expression, and eosinophil chemotactic activity in asthmatic sputum
12. Induced sputum eosinophil cationic protein (ECP) measurement in asthma and chronic obstructive airway disease (COAD)
13. Eosinophilic activation in cystic fibrosis
14. Late response to allergen is associated with increased concentrations of tumor necrosis factor-α and IL-5 in induced sputum
15. Respiratory symptoms, bronchial responsiveness, and cellular characteristics of induced sputum in elite swimmers
16. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease
17. 1-antitrypsin in sputum of asthmatic patients
18. DNase I acutely increases cystic fibrosis sputum elastase activity and its potential to induce lung hemorrhage in mice
19. Neutrophil elastase and elastase-rich cystic fibrosis sputum degranulate human eosinophils in vitro
20. Mucus hypersecretion in bronchiectasis. The role of neutrophil proteases
21. Validation of assays for inflammatory mediators in sputum
22. Levels of neutrophil elastase and cathepsin B activities, and cystatins in human sputum: Relationship to inflammation
23. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD
24. Interleukin-8 secretion and neutrophil recruitment accompanies induced sputum eosinophil activation in children with acute asthma
25. Sputum in severe exacerbations of asthma: Kinetics of inflammatory indices after prednisone treatment
26. Cellular and biochemical analysis of induced sputum from asthmatic and from healthy subjects
27. Airway mast-cell activation in asthmatics is associated with selective sputum eosinophilia
28. Lung function and sputum characteristics of patients with severe asthma during an induced exacerbation by double-blind steroid withdrawal
29. Analysis of plasma-protein leakage and local secretion in sputum from patients with asthma and chronic obstructive pulmonary disease
30. Asthma and natural colds: Inflammatory indices in induced sputum: A feasibility study
31. Proteinase/proteinase inhibitor imbalance in sputum sol phases from patients with chronic obstructive pulmonary disease. Suggestions for a key role played by antileukoprotease
32. Effects of inhaled histamine, methacholine and capsaicin on sputum levels of alpha 2-macroglobulin
33. Cytokine concentrations in sputum of asthmatic patients
34. Sputum cellular and cytokine responses to inhaled endothelin-1 in asthma
35. Distinct sputum cytokine profiles in cystic fibrosis and other chronic inflammatory airway disease
36. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis
37. Prednisone-dependent asthma: Inflammatory indices in induced sputum
38. Detection of transforming growth factor-β in sputum from patients with bronchial asthma by eosinophil survival assay and enzyme-linked immunosorbent assay
39. Analysis of induced sputum after air and ozone exposures in healthy subjects
40. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations
41. Interleukin-10 level in sputum is reduced in bronchial asthma, COPD and in smokers
42. Differences in interleukin-8 and tumor necrosis factor-α in induced sputum from patients with chronic obstructive pulmonary disease or asthma
43. TNF-α IL-8, soluble ICAM-1, and neutrophils in sputum of cystic fibrosis patients
44. Endothelin-1 levels in induced sputum samples from asthmatic and normal subjects
45. Eotaxin in induced sputum of asthmatics: Relationship with eosinophils and eosinophil cationic protein in sputum
46. Correlation between eotaxin level and eosinophil cationic protein in the induced sputum from asthmatic subjects
47. Increase of chemokine levels in sputum precedes exacerbation of acute asthma attacks
48. Inhaled IL-5 increases concentrations of soluble intracellular adhesion molecule-1 in sputum from atopic asthmatic subjects
49. Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis
50. Sputum matrix metalloproteinase-9: Tissue inhibitor of metalloproteinase-1 ratio in acute asthma
51. Leukotrienes in the sputum and urine of cystic fibrosis children
52. Induced sputum eicosanoid concentrations in asthma
53. Sputum cysteinyl leukotrienes increase 24 hours after allergen inhalation in atopic asthmatics
54. Lipid mediators in cystic fibrosis and chronic obstructive pulmonary disease
55. 2) and eosinophil cationic protein (ECP) in sputum from asthmatics
56. Total sputum nitrate plus nitrite is raised during acute pulmonary infection in cystic fibrosis
57. Markers of mucus secretion and DNA levels in induced sputum from asthmatic and from healthy subjects
58. Assays for cytokines
59. Cytokines
60. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis
61. Sputum peroxidase activity correlates with the severity of lung disease in cystic fibrosis
62. Imbalance between 95 kDa type IV collagenase and tissue inhibitor of metalloproteinases in sputum of patients with cystic fibrosis
63. Catalase, myeloperoxidase and hydrogen peroxide in cystic fibrosis
64. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation
65. Developments in immunological standardization
66. Variable estimates of cytokine levels produced by commercial ELISA kits: Results using international cytokine standards
67. Biological standardization of cytokines and growth factors
68. WHO cytokine standardization: Facilitating the development of cytokines in research, diagnosis and as therapeutic agents
69. Variables that affect assays for plasma cytokines and soluble activation markers
70. Cytokine immunoassays: Recommendations for standardisation, calibration and validation
71. Detection of and discrimination between total and free human interleukin-4 and free soluble interleukin-4 receptor by ELISA
72. Serum levels of soluble interleukin-2 receptor in asthma patients
73. Membrane-bound and soluble alpha IL-5 receptor mRNA in the bronchial mucosa of atopic and nonatopic asthmatics
74. Measurement of serum cytokines
75. Immunoassays for detecting cytokines: What are they really measuring?
76. High-avidity autoantibodies to cytokines
77. Alpha 2-macroglobulin: A binding protein for transforming growth factor-beta and various cytokines
78. Biology and biochemistry of the chemokines: A family of chemotactic and inflammatory cytokines
79. 2-macroglobulin
80. IL-8 in cystic fibrosis and its regulation by complexation with macromolecules
81. Free and complexed interleukin-8 in blood and bronchial mucosa in asthma
82. DNA actin bind and inhibit interleukin-8 function in cystic fibrosis sputa: In vitro effects of mucolytics
83. Neutrophil attractant protein-1-immunoglobulin G immune complexes and free anti-NAP-1 antibody in normal human serum
84. DNA concentration and in vitro responsiveness of purulent sputum in patients with cystic fibrosis, bronchiectasis, and acute exacerbations of chronic bronchitis
85. The effect of alpha 2 macroglobulin in commercial cytokine assays
86. Spontaneous and induced sputum to measure indices of airway inflammation in asthma
87. Salbutamol pretreatment does not change eosinophil percentage and eosinophilic cationic protein concentration in hypertonic saline-induced sputum in asthmatic subjects
88. Eosinophil cationic protein (ECP) and histamine levels in induced sputum are not affected by hypertonic saline inhalation
89. Fractional analysis of sequential induced sputum samples during sputum induction: Evidence that different lung compartments are sampled at different time points
90. Changes in sputum composition during sputum induction in healthy and asthmatic subjects
91. Effect of methacholine challenge on cellular composition of sputum induction
92. Changes in sputum composition between two inductions performed on consecutive days
93. Sequentially induced sputum in patients with asthma or chronic obstructive pulmonary disease
94. Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation
95. Measurement of inflammatory indices in induced sputum: Effects of selection of sputum to minimize salivary contamination
96. Comparison of two methods of processing induced sputum: Selected versus entire sputum
97. Induced sputum cell and fluid-phase indices of inflammation: Comparison of treatment with dithiothreitol vs phosphate-buffered saline
98. Dithiothreitol, a new protective reagent for SH groups
99. Human interleukin 4. The solution structure of a four-helix bundle protein
100. Unraveling the structure of IL-2
101. Three-dimensional structure of dimeric human recombinant macrophage colony-stimulating factor
102. Human cytokines
103. Effect of physical and chemical methods of homogenisation on inflammatory mediators in sputa of astmatics
104. Induced sputum: Validity of fluidphase IL-5 measurement
105. Spiking of sputum fluid phase indicates that interleukin-5 recovery is incomplete
106. Comparison of sputum processing techniques in cystic fibrosis
107. Bronchorrhoea - Separation of mucus and serum components in sol and gel phases
108. Osmolality of dispersed sputum: Effect of diluent fluids
109. Recovery of radiolabelled interleukin-5 (IL-5) from sputum fluid phase differs when estimated by gamma counter or immunoassay
110. Sputum handling for routine use to measure inflammation markers: Comparison of two methods
111. Eosinophil cationic protein in induced sputum as a marker of inflammation in asthmatic children
112. Increased detection of interleukin-5 in sputum by addition of protease inhibitors
113. Self-reactive antibodies (natural autoantibodies) in healthy individuals
114. Biochemical and functional characterization of soluble form of IL-5 receptor alpha (sIL-5R alpha). Development of ELISA system for detection of sIL-5R alpha
115. Circulating levels of soluble interleukin-6 receptor in patients with bronchial asthma
116. Activation of bronchial mucin proteolysis by 4-aminophenylmercuric acetate and disulphide bond reducing agents